Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit .BOSTON--(BUSINESS WIRE)--Nov. 27, 2024--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Adam Crystal, M.D., Ph.D., President, Research & Development of Tango Therapeutics, is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 1:30 PM ET.
波士頓--(商業資訊)--2024年11月27日--Tango Therapeutics, Inc.（納斯達克：TNGX）是一家致力於發現和提供下一代精準癌症藥物的臨牀階段生物技術公司，今天宣佈，Tango Therapeutics的研究與開發總裁Adam Crystal萬.D.，博士，已安排於2024年12月5日星期四下午1:30（東部時間）在派傑投資第36屆年度醫療會議上進行演講。
A live webcast of the presentation will be available under the "Events & Presentations" tab on the "Investors" page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
演講的現場網絡直播將在活動當天在公司網站的"投資者"頁面下的"活動與演講"標籤中提供。網絡直播的回放將在演講後90天內存檔在公司網站上。
About Tango Therapeutics
關於Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit .
Tango Therapeutics是一家致力於發現新藥物靶點並提供下一代精準醫學用於癌症治療的臨牀階段生物技術公司。Tango採用以患者爲中心的方式，利用合成致死的遺傳原理，發現和開發針對癌症關鍵靶點的治療方案。有關更多信息，請訪問。
View source version on businesswire.com:
在businesswire.com查看源版本：
Investor Contact:
Sam Martin/Andrew Vulis
Argot Partners
tango@argotpartners.com
Media Contact:
Amanda Brown Galgay
SVP, Corporate Communications, Tango Therapeutics
media@tangotx.com
投資者聯繫人：
薩姆·馬丁/安德魯·沃利斯
阿戈特夥伴
tango@argotpartners.com
媒體聯繫人：
阿曼達·布朗·加爾蓋
高級副總裁，通信，Tango Therapeutics
media@tangotx.com
Source: Tango Therapeutics, Inc.
來源：Tango Therapeutics, Inc.
譯文內容由第三人軟體翻譯。
